Skip to main content
. 2020 Jun 4;12(11):10070–10086. doi: 10.18632/aging.103298

Table 6. Complications and treatments of COVID-19 patients.

all (n=1000) age<60(n=473) 60-74(n=359) age≥75(n=168)
Complications, No. (%)
Shock 81 (8.1%) 26 (5.5%) 29 (8.1%) 26 (15.5%)*#
Acute cardiac injury 116 (11.6%) 19 (4%) 45 (12.5%)* 52 (31%)*#
Acute renal injury 29 (2.9%) 6 (1.3%) 12 (3.3%)* 11 (6.5%)*
Acute liver injury 64 (6.4%) 36 (7.6%) 23 (6.4%) 5 (3%)*
≥1 complication 191 (19.1%) 62 (13.1%) 68 (18.9%)* 61 (36.3%)*#
Only one complication 125 (12.5%) 49 (10.4%) 40 (11.1%) 36 (21.4%)*#
≥2 complications 66 (6.6%) 13 (2.7%) 28 (7.8%)* 25 (14.9%)*#
Admission to ICU, No. (%) 63 (6.3%) 20 (4.2%) 26 (7.2%) 17 (10.1%)*
ICU treatment duration, day, 7 (3,11) 7 (4,11) 10 (5,12) 4 (2,7)#
Median (IQR)
Oxygen therapy, No. (%)
Nasal catheter oxygen inhalation 661 (66.1%) 270 (57.1%) 261 (72.7%)* 130 (77.4%)*
Mask oxygen inhalation 314 (31.4%) 120 (25.4%) 120 (33.4%)* 74 (44%)*#
HFBHTI 91 (9.1%) 29 (6.1%) 35 (9.7%) 27 (16.1%)*#
Non-invasive mechanical ventilation 147 (14.7%) 46 (9.7%) 57 (15.9%)* 44 (26.2%)*#
Invasive mechanical ventilation 43 (4.3%) 15 (3.2%) 18 (5%) 10 (6%)
Medical treatment, No. (%)
Antiviral treatment 927 (92.7%) 435 (92%) 340 (94.7%) 152 (90.5%)
Antibiotic treatment 783 (78.3%) 362 (76.5%) 288 (80.2%) 133 (79.2%)
Antifungal treatment 32 (3.2%) 11 (2.3%) 15 (4.2%) 6 (3.6%)
Glucocorticoids 500 (50%) 220 (46.5%) 197 (54.9%)* 83 (49.4%)
Immunoglobulin therapy 513 (51.3%) 219 (46.3%) 200 (55.7%)* 94 (56%)*
Special treatment, No. (%)
CRRT 15 (1.5%) 6 (1.3%) 6 (1.7%) 3 (1.8%)
ECMO 2 (0.2%) 2 (0.4%) 0 (0%) 0 (0%)
ALSS 10 (1%) 6 (1.3%) 4 (1.1%) 0 (0%)

Abbreviation: ALSS: artificial liver support system; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IQR: interquartile range. P values indicate differences between male and female patients. * p<0.05 vs. <60 group. # p<0.05vs. 60-74 group.